China Resources Pharmaceutical Group Limited (CR Pharmaceutical) (Stock Code: 03320.HK) is a leading integrated pharmaceutical company in China, specializing in pharmaceutical manufacturing and commercial distribution of medicines, nutraceutical products and medical instruments. Since its listing , we have been included into a number of important capital market indexes, including Hang Seng Composite MidCap & SmallCap Index, Hang Seng China Central SOEs Index, Hang Seng SCHK China Central SOEs ESG 40 Index, Hang Seng SCHK China Central SOEs ESG Leaders Index, FTSE Global Equity Index Series, and Morgan Stanley Capital International (MSCI) China SMID Cap Index, etc.
Our subsidiaries include CR Pharmaceutical Commercial Group Co., Ltd., CR Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ), CR Double-Crane Pharmaceutical Co., Ltd. (600062.SH), CR Jiangzhong Pharmaceutical Group Co., Ltd. (600750.SH), Dong-E-E-Jiao Pharmaceutical Co., Ltd. (000423.SZ), China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ), China Resources Biopharmaceutical Co., Ltd., Sichuan Nigale Biotechnology Co., Ltd. and National Institute of Pharmaceutical R&D Co., Ltd., etc.
In 2025, CR Pharmaceutical achieved a revenue of CNY 269.57 billion and a net profit of CNY 9.65 billion.
We manufacture 928 kinds of products, including chemicals, traditional Chinese medicines(TCM), biological agents, nutraceutical products and medical instruments, etc., covering a wide range of therapeutic areas, such as cardiovascular, gastrointestinal and metabolism, high-volume intravenous infusion, pediatrics, respiratory system, dermatology, as well as blood products, coagulation disorders treatment and immune disease treatment. Our portfolio features many renowned brands such as "999" "Dong-E-E-Jiao" "Double-Crane" "Jiangzhong" "Boya Bio-pharmaceutical" "Zizhu" "Kun Zhong Yao-1381" "Nigale".
Our nationwide network covers 28 provinces, autonomous regions, and municipalities, serving over 260,000 clients. We provide highly specialized and efficient supply chain solutions to upstream and downstream partners. Additionally, we operate one of China's largest retail pharmacy networks, comprising 1,248 retail pharmacies, including 256 Direct-to-Patient (DTP) pharmacies (of which 192 are "Dual-Channel" pharmacies).
Guided by our lofty mission of "Safeguarding Human Health and Enhancing Quality of Life", CR Pharmaceutical is committed to seizing opportunities in China's evolving healthcare industry. By leveraging R&D innovation, strategic investment and M&A as dual engines, we aim to optimize resource allocation, propel the consolidation, enhancement and renovation of the industrial chain to drive business growth and industrial upgrading. Our goal is to become a trusted, innovation-driven leader in the pharmaceutical and healthcare sector, delivering high-quality development and creating sustainable value.
